Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
暂无分享,去创建一个
[1] M. Shibuya,et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1 , 2003, Nature Cell Biology.
[2] U. Rapp,et al. Craf-1 protein kinase is essential for mouse development , 1998, Mechanisms of Development.
[3] C. Pritchard,et al. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. , 2012, Genes & development.
[4] U. Rapp,et al. Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.
[5] C. Pritchard,et al. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene , 1996, Current Biology.
[6] H. Yao,et al. cAMP Activates MAP Kinase and Elk-1 through a B-Raf- and Rap1-Dependent Pathway , 1997, Cell.
[7] J. Otto,et al. Targeted Inactivation of the Isoprenylcysteine Carboxyl Methyltransferase Gene Causes Mislocalization of K-Ras in Mammalian Cells* , 2000, The Journal of Biological Chemistry.
[8] J. Rine,et al. Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis , 1997, Science.
[9] U. Rapp,et al. Generation of new mouse sarcoma viruses in cell culture. , 1978, Science.
[10] Boris N. Kholodenko,et al. Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling , 2014, Nature Cell Biology.
[11] Christof Fellmann,et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. , 2014, Cancer cell.
[12] C. Der,et al. Ras history , 2010, Small GTPases.
[13] J. Desai,et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. , 2019, Journal of Clinical Oncology.
[14] K. Xia,et al. Interaction of the protein kinase Raf-1 with 14-3-3 proteins. , 1994, Science.
[15] T. Veenstra,et al. Protein Phosphatase 2A Positively Regulates Ras Signaling by Dephosphorylating KSR1 and Raf-1 on Critical 14-3-3 Binding Sites , 2003, Current Biology.
[16] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[17] E. Castellano,et al. Functional specificity of ras isoforms: so similar but so different. , 2011, Genes & cancer.
[18] D. Cacchiarelli,et al. Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. , 2016, Cell reports.
[19] R. Stephens,et al. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis , 2019, Proceedings of the National Academy of Sciences.
[20] Susan S. Taylor,et al. Kinase Regulation by Hydrophobic Spine Assembly in Cancer , 2014, Molecular and Cellular Biology.
[21] David L. Brautigan,et al. Raf-1 activates MAP kinase-kinase , 1992, Nature.
[22] K. Flaherty,et al. BRAF, a target in melanoma , 2010, Cancer.
[23] T. Bonner,et al. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene , 1986, Molecular and cellular biology.
[24] Ying Cheng,et al. Current Development Status of MEK Inhibitors , 2017, Molecules.
[25] Steven J. M. Jones,et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.
[26] X. F. Zhang,et al. Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues , 1994, Molecular and cellular biology.
[27] Frank McCormick,et al. ras GTPase activating protein: Signal transmitter and signal terminator , 1989, Cell.
[28] Raf-1 and B-Raf promote protein kinase C theta interaction with BAD. , 2007, Cellular signalling.
[29] T. Veenstra,et al. CK2 Is a Component of the KSR1 Scaffold Complex that Contributes to Raf Kinase Activation , 2007, Current Biology.
[30] M. Reth,et al. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf , 2003, Oncogene.
[31] U. Rapp,et al. Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase* , 2011, The Journal of Biological Chemistry.
[32] Jiancheng Hu,et al. The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants , 2018, bioRxiv.
[33] T. Kawabe,et al. Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor κB Pathway and Cellular Transformation , 2004, Cancer Research.
[34] T. Tan,et al. DUSPs, to MAP kinases and beyond , 2012, Cell & Bioscience.
[35] P. Casey,et al. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. , 1995, Biochemistry.
[36] M. Wigler,et al. Complex formation between RAS and RAF and other protein kinases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[37] Yong Zhou,et al. Ras nanoclusters: Versatile lipid-based signaling platforms. , 2015, Biochimica et biophysica acta.
[38] Philippe P Roux,et al. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.
[39] K. Moelling,et al. Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.
[40] J. Troppmair,et al. Activation of NF-κB by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade , 1998, Oncogene.
[41] W. Kolch,et al. The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. , 2009, Cellular signalling.
[42] P. J. Belshaw,et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism , 1996, Nature.
[43] M. Therrien,et al. Regulation of RAF protein kinases in ERK signalling , 2015, Nature Reviews Molecular Cell Biology.
[44] Yoichi Matsubara,et al. Recent advances in RASopathies , 2015, Journal of Human Genetics.
[45] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[46] C. Marshall,et al. All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.
[47] N. Perrimon,et al. Requirement of the Drosophila raf homologue for torso function , 1989, Nature.
[48] F H Reynolds,et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[49] C. Der,et al. M-Ras/R-Ras3, a Transforming Ras Protein Regulated by Sos1, GRF1, and p120 Ras GTPase-activating Protein, Interacts with the Putative Ras Effector AF6* , 1999, The Journal of Biological Chemistry.
[50] G. Guy,et al. Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf* , 2002, The Journal of Biological Chemistry.
[51] P. Worley,et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells , 2002, Oncogene.
[52] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[53] P. Casey,et al. Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer , 2017, Molecular Cancer Therapeutics.
[54] Paul W. Sternberg,et al. C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation , 1993, Nature.
[55] D. Fry,et al. Chemical shift assignments and folding topology of the Ras-binding domain of human Raf-1 as determined by heteronuclear three-dimensional NMR spectroscopy. , 1994, Biochemistry.
[56] D. Bar-Sagi,et al. Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2 , 1996, Molecular and cellular biology.
[57] Laura M. Heiser,et al. Regulation of the Raf–MEK–ERK pathway by protein phosphatase 5 , 2006, Nature Cell Biology.
[58] Susan S. Taylor,et al. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.
[59] Peng-Fei Wang,et al. A patent review of BRAF inhibitors: 2013-2018 , 2019, Expert opinion on therapeutic patents.
[60] W. Kolch,et al. Negative regulation of Raf-1 by phosphorylation of serine 621 , 1996, Molecular and cellular biology.
[61] Min Han,et al. The C. elegans ksr-1 gene encodes a novel raf-related kinase involved in Ras-mediated signal transduction , 1995, Cell.
[62] Roland Seifert,et al. Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .
[63] B. Cochran,et al. p50cdc37 Acting in Concert with Hsp90 Is Required for Raf-1 Function , 1999, Molecular and Cellular Biology.
[64] B. Calabretta,et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. , 1999, Cancer research.
[65] Robert G. Parton,et al. Direct visualization of Ras proteins in spatially distinct cell surface microdomains , 2003, The Journal of cell biology.
[66] Walter Kolch,et al. Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation , 2015, Angewandte Chemie.
[67] L. Decoster,et al. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib , 2016, Oncotarget.
[68] J. Hancock,et al. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions , 2001, Oncogene.
[69] Jie Zhang,et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] M. Therrien,et al. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition , 2017, Nature Communications.
[71] T. Sturgill,et al. Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. , 1988, The Journal of biological chemistry.
[72] Nancy Y. Ip,et al. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF , 1991, Cell.
[73] D. Morrison,et al. Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner. , 1994, The Journal of biological chemistry.
[74] G. Piazza,et al. The RAS-Effector Interaction as a Drug Target. , 2017, Cancer research.
[75] Abran Q. Costales,et al. Discovery of RAF 265 : A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma , 2015 .
[76] W. Min,et al. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. , 2007, Cancer research.
[77] L. Ambrosio,et al. Drosophila Raf's N Terminus Contains a Novel Conserved Region and Can Contribute to Torso RTK Signaling , 2010, Genetics.
[78] R. Stephens,et al. Autoregulation of the Raf-1 serine/threonine kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[79] J. Frost,et al. p21 activated kinase 5 activates Raf‐1 and targets it to mitochondria , 2008, Journal of cellular biochemistry.
[80] Susan S. Taylor,et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF , 2011, Proceedings of the National Academy of Sciences.
[81] N. Hacohen,et al. sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways , 1998, Cell.
[82] S. Sebti. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. , 2005, Cancer cell.
[83] Tomoyasu Ishikawa,et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.
[84] Xiwen Ma,et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.
[85] M. Philips,et al. Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras Published, JLR Papers in Press, March 16, 2006. , 2006, Journal of Lipid Research.
[86] S. Welsh,et al. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma , 2015, Therapeutic advances in medical oncology.
[87] Mei Wang,et al. Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth , 2010, Oncogene.
[88] M. Barbacid,et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.
[89] Larissa V Furtado,et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. , 2014, Blood.
[90] S. O’Brien,et al. The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. , 1984, Science.
[91] Weiru Wang,et al. Ras inhibition via direct Ras binding--is there a path forward? , 2012, Bioorganic & medicinal chemistry letters.
[92] J. Rojas,et al. H-Ras-specific activation of NF-κB protects NIH 3T3 cells against stimulus-dependent apoptosis , 2003, Oncogene.
[93] R. Nussinov,et al. Mechanisms of Membrane Binding of Small GTPase K-Ras4B Farnesylated Hypervariable Region* , 2015, The Journal of Biological Chemistry.
[94] Susan S. Taylor,et al. Pseudokinases from a structural perspective. , 2013, Biochemical Society transactions.
[95] V. Sondak,et al. The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms , 2012, Clinical Cancer Research.
[96] M. Barbacid,et al. H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. , 2017, Cancer research.
[97] M. H. Cobb,et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338 , 2000, Current Biology.
[98] C. Pritchard,et al. A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression , 2005, Oncogene.
[99] K. Inouye,et al. Formation of the Ras Dimer Is Essential for Raf-1 Activation* , 2000, The Journal of Biological Chemistry.
[100] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .
[101] Kristina M. Ilieva,et al. Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models , 2014, Molecular Cancer Therapeutics.
[102] Stephen B. Long,et al. Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.
[103] M. Barbacid,et al. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. , 2005, Cancer cell.
[104] W. R. Bishop,et al. K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.
[105] Nadinath B. Nillegoda,et al. Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation , 2007, The Journal of cell biology.
[106] P. Workman,et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. , 2005, Cancer research.
[107] G. Tzivion,et al. Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.
[108] A. Brunet,et al. B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222. , 1995, Oncogene.
[109] W. Kolch,et al. Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.
[110] Timothy Travers,et al. Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain , 2018, Scientific Reports.
[111] A. Ashworth,et al. Identification of the sites in MAP kinase kinase‐1 phosphorylated by p74raf‐1. , 1994, The EMBO journal.
[112] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[113] Susan S. Taylor,et al. Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers , 2013, Cell.
[114] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[115] E. Krebs,et al. Identification of multiple epidermal growth factor-stimulated protein serine/threonine kinases from Swiss 3T3 cells. , 1990, The Journal of biological chemistry.
[116] Manuela Baccarini,et al. A balance between Raf-1 and Fas expression sets the pace of erythroid differentiation. , 2006, Blood.
[117] S. Ficarro,et al. Architecture of autoinhibited and active BRAF/MEK1/14-3-3 complexes , 2019, Nature.
[118] Abran Q. Costales,et al. Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. , 2015, ACS medicinal chemistry letters.
[119] C. Der,et al. RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.
[120] J. Hancock,et al. Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.
[121] C. Pritchard,et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. , 2005, Cancer research.
[122] S. Elledge,et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.
[123] W. Sellers,et al. Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. , 2020, Journal of medicinal chemistry.
[124] Roland L. Dunbrack,et al. Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors , 2014, Journal of medicinal chemistry.
[125] S. Subramaniam,et al. Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases , 2019, Science.
[126] R. Thapar,et al. NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. , 2004, Journal of molecular biology.
[127] G. Barton,et al. Emerging roles of pseudokinases. , 2006, Trends in cell biology.
[128] S. Sebti,et al. Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.
[129] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[130] A. Balmain,et al. A model for RAS mutation patterns in cancers: finding the sweet spot , 2018, Nature Reviews Cancer.
[131] Robert G Parton,et al. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[132] M. Barbacid,et al. RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling , 2018, Nature Medicine.
[133] Phillip T. Hawkins,et al. Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.
[134] P. Casey,et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. , 2007, The Journal of clinical investigation.
[135] A. King,et al. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling , 1997, Molecular and cellular biology.
[136] M. Atkins,et al. Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma , 2006, Clinical Cancer Research.
[137] Tianhai Tian,et al. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction , 2007, Nature Cell Biology.
[138] M. Vitale,et al. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation , 2012, Cell cycle.
[139] M. Barbacid,et al. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. , 2018, Cancer cell.
[140] H. Beug,et al. Raf-1 Antagonizes Erythroid Differentiation by Restraining Caspase Activation , 2002, The Journal of experimental medicine.
[141] F. McCormick,et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. , 2013, Cancer cell.
[142] P. Casey,et al. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo , 2014, Cancer biology & therapy.
[143] James Tsai,et al. RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.
[144] D. Morrison,et al. Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro , 1995, Molecular and cellular biology.
[145] Giulio Superti‐Furga,et al. Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.
[146] Marc Therrien,et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation , 2014, Nature Structural &Molecular Biology.
[147] E. Wagner,et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene , 2001, The EMBO journal.
[148] W. Fantl,et al. Activation of Raf-1 by 14-3-3 proteins , 1994, Nature.
[149] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[150] H. Horvitz,et al. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans , 1995, Cell.
[151] J. Yap,et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.
[152] M. Baccarini,et al. Raf-1 addiction in Ras-induced skin carcinogenesis. , 2009, Cancer cell.
[153] W. Kolch,et al. Tumor and Stem Cell Biology Heterogeneous Nuclear Ribonucleoprotein H Blocks Mst2-mediated Apoptosis in Cancer Cells by Regulating A-raf Transcription , 2022 .
[154] C. Crews,et al. Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[155] How to fool a wonder drug: truncate and dimerize. , 2012, Cancer cell.
[156] R. Zahedi,et al. Positive Regulation of A-RAF by Phosphorylation of Isoform-specific Hinge Segment and Identification of Novel Phosphorylation Sites* , 2008, Journal of Biological Chemistry.
[157] D. Morrison,et al. Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. , 2016, Molecular cell.
[158] Jing Chen,et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[159] G. Ladds,et al. Ras activation revisited: role of GEF and GAP systems , 2015, Biological chemistry.
[160] R. Lurz,et al. Two unrelated cell‐derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. , 1983, The EMBO journal.
[161] C. Pritchard,et al. A new mode of RAF autoregulation: a further complication in the inhibitor paradox. , 2013, Cancer cell.
[162] Yuri K Peterson,et al. A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity* , 2006, Journal of Biological Chemistry.
[163] KL Pennington,et al. The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein–protein interactions , 2018, Oncogene.
[164] P. Casey,et al. Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.
[165] W. Kolch,et al. Spatial regulation of ARAF controls the MST2-Hippo pathway , 2017, Small GTPases.
[166] C. Marshall,et al. Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation. , 1995, The EMBO journal.
[167] D. Adams,et al. Synthetic lethality: emerging targets and opportunities in melanoma , 2017, Pigment cell & melanoma research.
[168] R. Gibbs,et al. S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase. , 2012, ACS medicinal chemistry letters.
[169] D. Morrison,et al. The complexity of Raf-1 regulation. , 1997, Current opinion in cell biology.
[170] M. Weber,et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.
[171] M. Bergo,et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. , 2008, Blood.
[172] Michael B Yaffe,et al. How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesis , 2002, FEBS letters.
[173] S. Cook,et al. Inhibition by cAMP of Ras-dependent activation of Raf. , 1993, Science.
[174] K. Moelling,et al. Serine- and threonine-specific protein kinase activities of purified gag–mil and gag–raf proteins , 1984, Nature.
[175] K. Flaherty,et al. Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.
[176] R. Murphy,et al. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition , 2017, The EMBO journal.
[177] T. Haystead,et al. Functional expression of a MAP kinase kinase in COS cells and recognition by an anti‐STE7/byrl antibody , 1993, FEBS letters.
[178] Marc Therrien,et al. MEK drives BRAF activation through allosteric control of KSR proteins , 2018, Nature.
[179] D J Glass,et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. , 1999, Science.
[180] F. McCormick,et al. Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. , 1994, Science.
[181] T. Sturgill,et al. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[182] M. Nikiforova,et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.
[183] Carol L. Williams. A new signaling paradigm to control the prenylation and trafficking of small GTPases , 2013, Cell cycle.
[184] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[185] C. Pritchard,et al. MEK kinase activity is not necessary for Raf‐1 function , 2001, The EMBO journal.
[186] M. Farrar,et al. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization , 1996, Nature.
[187] Jonathan A. Cooper,et al. Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.
[188] S. Wiese,et al. B- and C-RAF Display Essential Differences in Their Binding to Ras , 2007, Journal of Biological Chemistry.
[189] Shinichi Suzuki,et al. BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.
[190] Jonathan A. Cooper,et al. A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[191] K. Xia,et al. The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[192] W. Hahn,et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.
[193] Aaron N. Chang,et al. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions , 2017, Nature Methods.
[194] P. Casey,et al. High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors* , 2003, Journal of Biological Chemistry.
[195] P. Casey,et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. , 2004, The Journal of clinical investigation.
[196] David T. W. Jones,et al. Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma , 2011, Acta Neuropathologica.
[197] A. King,et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338 , 1998, Nature.
[198] N. Tsuchida,et al. RAS Mutations in Human Cancers: Roles in Precision Medicine. , 2019, Seminars in cancer biology.
[199] O. Carugo,et al. From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-α kinase activity , 2009, The Journal of cell biology.
[200] D. Morrison,et al. Identification of the major phosphorylation sites of the Raf-1 kinase. , 1993, The Journal of biological chemistry.
[201] J. Homsi,et al. Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma , 2017, Case reports in oncological medicine.
[202] B. Neyns,et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. , 2012, Melanoma research.
[203] R. Nussinov,et al. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. , 2015, Structure.
[204] A. Resnick,et al. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles , 2017, Oncogene.
[205] D. Bar-Sagi,et al. Regulating the regulator: post-translational modification of RAS , 2011, Nature Reviews Molecular Cell Biology.
[206] D. Elder,et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations , 2009, Oncogene.
[207] Y. Ueyama,et al. B-raf, a new member of the raf family, is activated by DNA rearrangement , 1988, Molecular and cellular biology.
[208] T. Roberts,et al. Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[209] Marc Therrien,et al. A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.
[210] D. Hardie,et al. Identification of Raf‐1 Ser621 kinase activity from NIH 3T3 cells as AMP‐activated protein kinase , 1997, FEBS letters.
[211] Walter Kolch,et al. Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.
[212] J. Miyazaki,et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. , 2004, The Journal of clinical investigation.
[213] N. Dumaz,et al. Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles , 2016, Oncotarget.
[214] T. Wirth,et al. Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[215] Christopher J. Staples,et al. Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter , 2008, The Biochemical journal.
[216] C. Der,et al. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment , 2016, Cancers.
[217] Alfred Wittinghofer,et al. Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction , 2008, Biological chemistry.
[218] R. Marais,et al. S338 Phosphorylation of Raf-1 Is Independent of Phosphatidylinositol 3-Kinase and Pak3 , 2001, Molecular and Cellular Biology.
[219] J. Feramisco,et al. Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins , 1984, Nature.
[220] O. Abdel-Wahab,et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.
[221] M. Baccarini,et al. Knock‐in(g) RAF for a loop , 2016, The EMBO journal.
[222] M. Digilio,et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum , 2009, Human mutation.
[223] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[224] D. K. Treiber,et al. Ins and outs of kinase DFG motifs. , 2013, Chemistry & biology.
[225] E. Petricoin,et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.
[226] A. Wittinghofer,et al. The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue , 1995, Nature.
[227] Ariana Peck,et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. , 2014, Cancer cell.
[228] L. Chin,et al. The Brothers RAF , 2010, Cell.
[229] K. Flaherty,et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[230] A. Baldwin,et al. Oncogenic Ras Enhances NF-κB Transcriptional Activity through Raf-dependent and Raf-independent Mitogen-activated Protein Kinase Signaling Pathways* , 1999, The Journal of Biological Chemistry.
[231] T. Bonner,et al. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. , 1987, Nucleic acids research.
[232] C. Fuchs,et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. , 2002, Molecular cancer therapeutics.
[233] W. Kolch,et al. Raf-1 and B-Raf promote protein kinase C θ interaction with BAD , 2007 .
[234] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[235] S. Mayor,et al. GPI-anchored proteins are organized in submicron domains at the cell surface , 1998, Nature.
[236] W. Kolch,et al. Cyclic AMP-Dependent Kinase Regulates Raf-1 Kinase Mainly by Phosphorylation of Serine 259 , 2002, Molecular and Cellular Biology.
[237] J. Hancock,et al. Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.
[238] U. Rapp,et al. Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.
[239] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[240] J. Frost,et al. Phosphorylation of Raf-1 by p21-activated Kinase 1 and Src Regulates Raf-1 Autoinhibition* , 2003, The Journal of Biological Chemistry.
[241] T. Bonner,et al. Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611 , 1984, Nature.
[242] P. Casey,et al. The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein , 1991, Molecular and cellular biology.
[243] C. Ottmann,et al. Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling , 2010, Molecular and Cellular Biology.
[244] Henry C. Chang,et al. KSR, a novel protein kinase required for RAS signal transduction , 1995, Cell.
[245] S. Braun,et al. Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants , 2016, The EMBO journal.
[246] Susan S. Taylor,et al. Kinases and Pseudokinases: Lessons from RAF , 2014, Molecular and Cellular Biology.
[247] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[248] P. Casey,et al. Enzymatic modification of proteins with a geranylgeranyl isoprenoid. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[249] J. Small,et al. Raf-1 regulates Rho signaling and cell migration , 2005, The Journal of cell biology.
[250] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[251] M. Pacher,et al. Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association* , 2002, The Journal of Biological Chemistry.
[252] T. Kawabe,et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.
[253] Wei Cheng,et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. , 2016, Cancer letters.
[254] T. Hunter,et al. Cdc37: a protein kinase chaperone? , 1997, Trends in cell biology.
[255] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[256] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[257] C. Kozak,et al. A new oncogene, c-raf, is located on mouse chromosome 6 , 1984, Journal of virology.
[258] J. Avruch,et al. An intact Raf zinc finger is required for optimal binding to processed Ras and for ras-dependent Raf activation in situ , 1997, Molecular and cellular biology.
[259] A. Eychène,et al. Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. , 1996, Oncogene.
[260] PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation , 2017, Molecular Cancer.
[261] K. Guan,et al. Positive and negative regulation of Raf kinase activity and function by phosphorylation , 2001, The EMBO journal.
[262] W. Kabsch,et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.
[263] A. Nishi,et al. Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain* , 2015, The Journal of Biological Chemistry.
[264] C. Der,et al. RAS Mutations Are Not Created Equal. , 2019, Cancer discovery.
[265] N. Rosen,et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[266] K. Dutta,et al. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling , 2016, Cell.
[267] T. Bonner,et al. Structure and biological activity of human homologs of the raf/mil oncogene , 1985, Molecular and cellular biology.
[268] J. Becker,et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.
[269] P. Casey,et al. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. , 1998, Biochemistry.
[270] D. Morrison,et al. Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.
[271] M. Baccarini,et al. Raf-1 sets the threshold of Fas sensitivity by modulating Rok-α signaling , 2005, The Journal of cell biology.
[272] John Calvin Reed,et al. Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.
[273] J. Troppmair,et al. The ins and outs of Raf kinases. , 1994, Trends in biochemical sciences.
[274] P. Casey,et al. Post-prenylation-processing enzymes as new targets in oncogenesis , 2005, Nature Reviews Cancer.
[275] W. Kolch,et al. Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.
[276] S. Wiese,et al. Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons , 2001, Nature Neuroscience.
[277] P. Thompson,et al. The Raf-1 serine-threonine kinase is a substrate for the p56lck protein tyrosine kinase in human T-cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[278] R. Benz,et al. Negative regulation of mitochondrial VDAC channels by C-Raf kinase , 2002, BMC Cell Biology.
[279] T. Brummer,et al. B-Raf activation loop phosphorylation revisited , 2016, Cell cycle.
[280] C. Der,et al. Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[281] P. Casey,et al. p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[282] P. Casey,et al. Protein prenylation: unique fats make their mark on biology , 2016, Nature Reviews Molecular Cell Biology.
[283] C. Der,et al. Elucidation of Binding Determinants and Functional Consequences of Ras/Raf-Cysteine-rich Domain Interactions* , 2000, The Journal of Biological Chemistry.
[284] Zhongzhou Chen,et al. Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis , 2018, Science Signaling.
[285] A. Neri,et al. Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP. , 1994, The Journal of biological chemistry.
[286] P. Dent,et al. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. , 1993, Science.
[287] J. Frost,et al. B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms* , 2005, Journal of Biological Chemistry.
[288] P. Allen,et al. Interaction of 14-3-3 with Signaling Proteins Is Mediated by the Recognition of Phosphoserine , 1996, Cell.
[289] M. Therrien,et al. A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila. , 2006, Genes & development.
[290] J. Field,et al. p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association* , 2005, Journal of Biological Chemistry.
[291] A. Sweet-Cordero,et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.
[292] W. Kolch,et al. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells , 1991, Nature.
[293] T. Haystead,et al. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. , 1992, Science.
[294] Ming Zhou,et al. Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.
[295] A. von Deimling,et al. Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.
[296] Junfeng Xia,et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.
[297] C. Der,et al. Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.
[298] P. Casey,et al. A Small Molecule Inhibitor of Isoprenylcysteine Carboxymethyltransferase Induces Autophagic Cell Death in PC3 Prostate Cancer Cells*♦ , 2008, Journal of Biological Chemistry.
[299] D. Barford,et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.
[300] N. Kohl,et al. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.
[301] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[302] D. Morrison,et al. 14-3-3 Proteins: diverse functions in cell proliferation and cancer progression. , 2011, Seminars in cell & developmental biology.
[303] D. Morrison,et al. Ras-Mediated Activation of the Raf Family Kinases. , 2019, Cold Spring Harbor perspectives in medicine.
[304] Evert Bosdriesz,et al. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.
[305] Jonathan A. Cooper,et al. Identification of Residues in the Cysteine-rich Domain of Raf-1 That Control Ras Binding and Raf-1 Activity* , 1998, The Journal of Biological Chemistry.
[306] R. Benz,et al. Regulation of glycolysis by Raf protein serine/threonine kinases. , 2002, Advances in enzyme regulation.
[307] Mark R. Smith,et al. Requirement for c-ras proteins during viral oncogene transformation , 1986, Nature.
[308] K.,et al. KSR stimulates Raf-1 activity in a kinase-independent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[309] Mark R. Smith,et al. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells , 1985, Nature.
[310] Jiancheng Hu,et al. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho–Ser-621 in the C terminus of CRAF , 2018, The Journal of Biological Chemistry.
[311] K. Guan,et al. Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601 , 2000, The EMBO journal.
[312] D. Tuveson,et al. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.
[313] Alma L. Burlingame,et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK , 2011, Nature.
[314] P. Casey,et al. Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[315] Susan S. Taylor,et al. Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.
[316] Christopher L. McClendon,et al. A dynamic hydrophobic core orchestrates allostery in protein kinases , 2017, Science Advances.
[317] T Takahashi,et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis , 2001, EMBO reports.
[318] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[319] O. Ilkayeva,et al. Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism , 2014, Oncogene.
[320] A. Borczuk,et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. , 2010, Carcinogenesis.
[321] H. Mott,et al. The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.